

---

**From:** jeffrey E. <jeevacation@gmail.com>  
**Sent:** Friday, November 3, 2017 4:53 AM  
**To:** Masha Drokova  
**Subject:** Re:

He is not an investor type . He is s partner at a fi=m but used to be at Microsoft. Just use him for advice

On Thu, Nov 2, 2017 at 11:13 PM Masha Drokova & [REDACTED]  
>wrote:

Thank you for the comprehensive feedback Steven.

For me the main value is =hat the system is an order of magnitude cheaper than existing technologies= premised on leveraging data to help users see what daily elements are aff=cting their blood sugar, and predicting dangerous highs and lows before th=y happen so they can take actions beforehand. To date, their beta app has lowered bl=od sugar averages in over 55% of users 2x better than the world's most=prescribed diabetes drug, Metformin. Which means that with the help of the=dated diabetes would need to use less drugs. However I'd agree on complexity of r=egulations and saturation on the market.

<=div>I run Day One Ventures fund and based in San Francisco. I'd be happ= to connect in person sometime to learn about about your experience and te=l about our investments and opportunities I see.

On Nov 2, 2017, at 3:24 PM, Steven Sinofsky [REDACTED] wrote:

Greet=ngs Masha,

I apologize for the delay. I was=at some events in in UK where I did not have connectivity.

<=div>

I have worked on a related portfolio company so I will have to be=a bit abstract on the specifics of this opportunity. So please excus= these brief thoughts. Also, the only information I had was what was provi=ed in your mail which was limited relative to any detailed analysis.

=div>

\* In general the challenge with glucose measurement is =he finger prick. Any device that relies on this will only be marginally be=ter than any other device, whether or not there is software or a slightly =ore convenient measuring device. This is a statement about the inconvenien=e of a prick (and long term challenges) but also the medical challenges on=relying on that point in time.

\* My sense is that going down the=path of an innovation, that still has a prick, but requires a level of FDA=approval is a difficult one to approach.

\* This is a very crowde= space. There are a lot of apps, a lot of measuring devices, a lot of mixt=res of app and measuring devices. It is very difficult to avoid appearing =s a commodity to consumers.

\* While I understand there is potent=al to see innovation using novel approaches to analysis of data, it is not=clear to me how much better the approach can be for an individual with dat=.

\* The real opportunity I might see is around measuring glucose=or some related telemetry to assist in compliance that is outside the scope of a finger prick and measuring glucose directly. It seems like we should=have some other data point upon which to apply machine learning.

I hope this helps...any friend of JE is a friend of mine.</=iv>

On Nov 1, 2017, at 4:43 PM, Masha Drokova [REDACTED] =rote:

Thank you= Jeffrey. Steve, great meeting you.  
Would appreciate your =eedback

On Nov 1, 2017, at 9:31 AM, jeffrey E. <jeevacation@gmail.com> wrote:

steve ca= you give some guidance

On Wed, Nov 1, 2017 at 12:20 PM, Masha Drokova <<= [REDACTED]

='m looking to invest at the company doing AI-based glucose monitoring =system for people with diabetes. We made tech evaluation, talked to a=few experts and more a question about the market and regulations. Likely n=, because it's complex area, but still thinking of them. </=pan>

</=pan>

May be=someone in your network who knows this area and can advise on this kind of=tech?

Center Health

Deck:

<=ont><https://drive.google.com/file/d/0B5O93D3IJArEbXB=dII4elVob0U/view>  
<<https://drive.google.com/file/d/0B5O93D3IJArEbXBsdII4=IVob0U>>

<=ont face="Roboto-Regular">Our memo:

<https://docs.google.com/document/d/1M7ZV7VEI8CTnb4EtYWFH2sq5dcC=0PM6g1AlcwrlOtM>  
<<https://docs.google.com/document/d/1M7ZV7VEI8CTnb4EtYWFH2sq5dcCm0PM6g1AlcwrlOtM>>

Center Health is building an AI-based glucose monitoring system for the 1 in 11 Americans =who suffer from diabetes, based on machine learning and their personalized AI, Aria. Users subscribe to their disposable test strips, a \$14B/yr U= market, which are delivered monthly, as Aria learns about their diabetes and prompts behavioral changes to lower blood sugar. The system is an order of magnitude cheaper than existing technologies, premised on leveraging data to help users see what daily elements are affecting their=blood sugar, and predicting dangerous highs and lows before they happen.=C2◆

Pros

- Existing glucometers from big companies are very old-fashioned and outdated, those companies make their revenue from overpriced strips
- Direct competitors, such as iHealth and Dario have negative customer reviews and minor
- Uses FDA-approved circuits to get the approval in an automated manner

#### Cons

- Enormous pressure both from the industry players and companies such as Apple and Google that try to develop non-invasive glucose monitoring that will wipe out test strip products
- ◆=94 Hardware startup without a product to sell yet, finalizing the development
- Young team
- </=iv>

--

conversation-id 25269 date-last-viewed 0 date-received 1509684786 flags 8590195717  
gmail-label-ids 7 6 remote-id 764740